Piramal Pharma is among the key stocks in focus today following its Q1 FY27 performance. The company remains active across contract development and manufacturing, critical-care products and consumer healthcare, giving it a diversified revenue base. The stock is among the companies highlighted by the market for today’s trading session.
Investors are particularly interested in the performance of its CDMO business and the company’s ability to maintain growth while improving profitability. Management commentary on order inflows, capacity utilisation and international demand will be important for assessing the FY27 outlook.
